Estimates
Source: S&P Capital IQ consensus via Xpressfeed · Generated 2026-07-28.
FY2028 normalized EPS marked up ~7% in 90 days while revenue holds flat
The lift is recent: over the prior six months both revenue lines and FY2027 EPS were trimmed 2–3%, so the 90-day EPS upgrade reads as a partial recovery rather than a fresh upcycle.
Currency: USD · Scale: money in millions, absolute · Point-in-time consensus; Δ90d is Now versus 90d.
| Metric | FY | 180d | 90d | 30d | Now | Δ90d |
|---|---|---|---|---|---|---|
| EPS (normalized) | FY2027 | $11.03 | $10.59 | $10.77 | $10.77 | +1.8% |
| EPS (normalized) | FY2028 | — | $10.52 | $11.22 | $11.22 | +6.7% |
| Revenue | FY2027 | $5.66bn | $5.55bn | $5.55bn | $5.55bn | +0.0% |
| Revenue | FY2028 | $6.07bn | $5.87bn | $5.88bn | $5.87bn | +0.1% |
Beat / miss record
Current sequences by metric: Revenue: 8 consecutive beats; EPS (normalized): 2 consecutive beats.
Currency: USD · Scale: money in millions, absolute · Consensus is captured before each actual first became effective.
| Quarter | Metric | Consensus | Actual | Surprise | Outcome |
|---|---|---|---|---|---|
| Q1 FY2026 | Revenue | $1.26bn | $1.27bn | +0.3% | Beat |
| Q1 FY2026 | EPS (normalized) | $1.99 | $2.05 | +2.7% | Beat |
| Q4 FY2025 | Revenue | $1.27bn | $1.27bn | +0.1% | Beat |
| Q4 FY2025 | EPS (normalized) | $2.22 | $2.30 | +3.7% | Beat |
| Q3 FY2025 | Revenue | $1.23bn | $1.27bn | +2.6% | Beat |
| Q3 FY2025 | EPS (normalized) | $2.15 | $1.99 | -7.1% | Miss |
| Q2 FY2025 | Revenue | $1.21bn | $1.22bn | +0.9% | Beat |
| Q2 FY2025 | EPS (normalized) | $1.89 | $1.90 | +0.4% | Beat |
| Q1 FY2025 | Revenue | $1.19bn | $1.19bn | +0.4% | Beat |
| Q1 FY2025 | EPS (normalized) | $1.97 | $1.86 | -5.2% | Miss |
| Q4 FY2024 | Revenue | $1.18bn | $1.19bn | +1.1% | Beat |
| Q4 FY2024 | EPS (normalized) | $1.73 | $1.97 | +13.8% | Beat |
| Q3 FY2024 | Revenue | $1.14bn | $1.15bn | +0.3% | Beat |
| Q3 FY2024 | EPS (normalized) | $1.40 | $1.80 | +27.9% | Beat |
| Q2 FY2024 | Revenue | $1.11bn | $1.12bn | +0.9% | Beat |
| Q2 FY2024 | EPS (normalized) | $1.28 | $1.43 | +11.4% | Beat |
Revenue compounds ~6% a year with EBITDA and free cash flow modeled to grow faster
Currency: USD · Scale: money in millions, absolute · YoY uses the prior fiscal year from the feed; analyst count and range use the first displayed period.
| Metric | FY2026E | FY2027E | FY2028E | YoY | Analysts | Low / high |
|---|---|---|---|---|---|---|
| Revenue | $5.24bn | $5.55bn | $5.87bn | +5.9% | 17 | $5.20bn / $5.26bn |
| EBITDA | $1.75bn | $1.89bn | $2.09bn | +10.3% | 14 | $1.73bn / $1.77bn |
| Free cash flow | $1.80bn | $1.95bn | $2.15bn | +7.8% | — | — |
Outer-year GAAP EPS is contested: FY2028 spans $9.02 to $13.28
Coverage falls from 13 analysts on FY2027 to 8 on FY2028, so the wider FY2028 band partly reflects thinner participation rather than pure conviction spread.
Currency: USD · Scale: money in millions, absolute · Spread/mean is absolute high-low divided by absolute mean.
| Metric | Period | Mean | Low–high | Spread/mean | Analysts |
|---|---|---|---|---|---|
| EPS (GAAP) | FY2027E | $8.97 | $7.49–$10.75 | 36.3% | 13 |
| EPS (GAAP) | FY2028E | $10.93 | $9.02–$13.28 | 38.9% | 8 |
Street split buy-to-hold with no sells; targets span $83–$190, median $100
The mean target sits above the median, lifted by the lone $190 high; nine buy-side ratings face eight holds.
Currency: USD · Scale: money in millions, absolute · Analyst counts shown explicitly.
| Street view | Reading | Analysts |
|---|---|---|
| Recommendation mix | Buy 7, Outperform 2, Hold 8, Underperform 0, Sell 0 | 17 |
| Consensus score | 2.06 | 17 |
| Target price | mean $111.9; median $100.0; high $190.0; low $83.00 | 15 |
Normalized-EPS and FY2029 consensus rest on very few analysts
Annual normalized-EPS consensus draws on just 1–3 analysts and FY2029 revenue/EBITDA on 1–2, so treat the outer-year EPS levels and momentum as indicative. GAAP EPS, with 8–13 estimates, is far better covered.